Helsinki, Finland, 30 September 2025: The board of Nordhealth AS (the "Company") has today approved the allocation of a maximum of 7,217,260 options linked to the Company's shares under an incentive scheme (the "Options") to members of the Company's executive management and key employees.

The Options vest based on a combination of time-based and share price-based performance. The time-based vesting is quarterly, over 4 years (1-year cliff). The performance-based vesting requires a minimum of 11% annual compounding growth in the share price from the start date (i.e. 10% or less annual growth means no options vest). The maximum Options vest if 25% or higher compounding share price growth has been achieved. There is a linear increase in vesting between 10% and 25%.

The vested Options may be exercised in designated exercise windows during a five year period subject to a possible extension of three additional years. The settlement of the Options may consist of shares on a one-for-one basis and/or cash at the discretion of the Company.

The following primary insiders and a close associate have been granted Options:

• Charles MacBain, CEO of the Company, was granted a maximum of 2,405,753 Options.
• Alexander Cram, CFO of the Company, was granted a maximum of 1,202,877 Options.
• A1KW B.V., a close associate of Karan Wallia, Therapy BU CEO, was granted a maximum of 2,405,753 Options.

Please refer to the attached notifications of trading for further details.

For further information, please contact:

Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200

Alexander Cram, CFO alexander.cram@nordhealth.com +32 470 69 30 20

This information is subject to disclosure requirements set out in the Market Abuse Regulation EU 596/2014 Article 19 and the Norwegian Securities Trading Act Section 5-12.